Relmada Therapeutics, Inc. (RLMD) Buy Target – $39.62 – Sell Target – $46.81

Trade Setup

Buy Target – $39.62
Sell Target – $46.81

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions.


Discover Top Stocks with TradersPro

X